tbuckley/cabot-search huggingface dataset:
Sex segregation and sport
Authors: Arne Ljungqvist
Journal: British Journal of Sports Medicine (2017)

After the second world war, success in elite sport slowly became increasingly important for both the individual athlete and his/her country. Since success in most sports depends on physical strength, men usually outperform women to a significant degree due to their higher levels of the male sex hormone testosterone which is a powerful androgenic-anabolic substance. Consequently, it also became increasingly important to protect female competitions from male imposters. Procedures for this purpose were introduced as from the 1960s and named ‘Gender verification’. As science developed, however, the procedures were found to be either unscientific or unethical, or both. After a lengthy struggle, the International Association of Athletics Federations (IAAF) was the first international sports organisation to abandon so-called gender verification in 1991.1 Eight years later, the IOC did the same, and the remaining international sports federations followed suit. At that time, the issue of participation of transgender athletes was not specifically addressed in sport.

In 2003, a National Olympic Committee asked the …
Abstract 17376: Novel Non-contrast MRI Technique for Visualization of Ablation Lesions
Authors: Eugene G Kholmovski, Ravi Ranjan, Nathan Angel, Nassir Marrouche
Journal: Circulation (2015)

Introduction: Late gadolinium enhanced MRI (LGE-MRI) is widely used to assess RF ablation lesions. However, this technique requires contrast injection and lesion visibility changes with time after injection. Non-contrast T1-weighted (T1w) MRI is only applicable to reliably visualize acute (&lt; 7 days) RF lesions. Hypothesis: T2*-weighted MRI can be used to visualize ablation lesions. Methods: Novel non-contrast MRI technique for sub-acute (&gt; 7 days) lesion visualization has been developed. This T2*-weighted technique exploits the difference in susceptibility between normal and ablated myocardium. Transformation of hemoglobin from blood vessels damaged during ablation into hemosiderin reduces T2* of ablated tissues. To validate the proposed technique RF ablations were performed in 3 canines using ThermoCool catheter (Biosense Webster) at 30 Watts for 30 seconds. Imaging studies were performed on a 3T MRI scanner (Verio, Siemens) at 0, 1, 4, and 8 weeks post-ablation. Scan protocol included T1w, T2*, and LGE scans with resolution of 1.25x1.25x2.5 mm. Results: Representative T1w, T2*, and LGE images are shown in Figure 1. All RF lesions (n=13) were readily detectable on non-contrast T1w images acquired acutely (Fig. 1a). Lesion visibility in T1w was drastically reduced 1 week post-ablation (Fig. 1b). Visibility of the lesions in T2* images improves with time after ablation (Fig. 1c-e). Lesions have hypointense boundaries in T2* images acquired 1 and 4 weeks post-ablation. Whole lesions are hypointense in T2* images acquired 8 weeks post-ablation. Strong correlation (R2=0.9747) between lesions volumes estimated from LGE and T2* acquired 8 weeks post-ablation was found (Fig. 2). Conclusions: Non-contrast T2* technique for visualization of RF ablations has been developed and validated. The technique can be used to detect RF lesions as early as a week post-ablation. T2* contrast of the lesions improves with time after ablation as amount of hemosiderin increases.
Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).
Authors: Katrin Marie Sjoquist, Nick Pavlakis, Andrew James Martin, Eric Tsobanis, Sonia Yip, Yung-Jue Bang, Thierry Alcindor, Christopher J. O'Callaghan, Kohei Shitara, Tanios S. Bekaii-Saab, Axel Grothey, Li-Tzong Chen, John Simes, John Raymond Zalcberg, David Goldstein
Journal: Journal of Clinical Oncology (2017)

TPS4136 Background: AGOC has a poor prognosis with no established standard treatment following failure of chemotherapy (CT). Regorafenib (BAY 73-4506)(REG) is an oral multi-kinase inhibitor targeting kinases involved in angiogenesis (VEGFR1-3, TIE-2), tumor microenvironment (PDGFR-β, FGFR), and oncogenesis (RAF, RET and KIT). INTEGRATE (phase 2) demonstrated REG was highly effective in prolonging PFS across a range of AGOC pts, with a positive OS trend. Regional differences were found in magnitude of effect, but REG was effective in all regions/subgroups. The phase 3 INTEGRATE II will explore whether REG is effective in prolonging survival in patients overall, and in the Asian sub-population. Methods: International (Australia/New Zealand (NHMRC CTC); Canada (CCTG), Korea, Japan, Taiwan, USA (ACCRU)) randomised phase III, double-blind, placebo-controlled trial with 2:1 (REG:placebo)(PBO) randomisation and stratification by: Location of tumour, Geographic region, prior VEGF inhibitors. Eligible patients (histologically confirmed AGOC), with evaluable metastatic or locally advanced disease refractory to, or relapsed following second line CT, will receive best supportive care plus 160mg REG or matched placebo orally on days 1-21 of each 28 day cycle until disease progression or prohibitive adverse events. Primary endpoint is OS. Secondary endpoints: PFS, response rate, quality of life, safety, identification of prognostic/predictive biomarkers for study endpoints, and REG PK across geographical regions. 350 patients (50% from Asia) randomized in a 2:1 ratio will provide 90% power to detect a hazard ratio (HR) for OS of 0.67 with a 2-sided α of 0.05 assuming PBO median survival is 4.5 mos. The sample size accommodates 2 interim analyses undertaken at 1/3 and 2/3 of required events. As of January 2017, 12 of 28 planned ANZ sites are open, with 4 patients enrolled. Regulatory approval has been received for 12 Canadian sites, and 12 Korean sites. Korean recruitment is expected to commence in February 2017. Regulatory submissions are pending in Taiwan, Japan, and the USA. Clinical trial information: NCT02773524.
Comparative study of two PD-L1 expression assays in patients with non-small cell lung cancer (NSCLC).
Authors: Zheng Feng, Michael Schlichting, Christoph Helwig, Vikram K. Chand, Arnold Gelb, Hulin Jin, Hans Juergen Grote
Journal: Journal of Clinical Oncology (2017)

e20581 Background: Response to anti–PD-L1/PD-1 therapy in patients with NSCLC has been associated with tumor PD-L1 expression. Avelumab is a fully human anti‒PD-L1 IgG1 antibody that has shown antitumor activity in advanced NSCLC, with a trend for greater efficacy in patients with PD-L1+ vs PD-L1– NSCLC tumors, as assessed using a proprietary PD-L1 assay in development (Dako, Carpinteria, CA; based on antibody clone 73-10, Merck KGaA, Darmstadt, Germany). This study compares the analytical performance of the 73-10 assay with the FDA-approved PD-L1 IHC 22C3 pharmDx diagnostic assay (Dako) in NSCLC tumors. Methods: Formalin-fixed paraffin-embedded NSCLC tumor samples were obtained from a commercial source and from a study of first-line (1L) avelumab in patients with advanced NSCLC (NCT01772004). Tumor membrane PD-L1 expression was assessed with the 73-10 and 22C3 assays by immunohistochemistry. Correlation between assays was determined at different PD-L1 cut-off levels. Results: In initial staining of commercial NSCLC samples, the 73-10 assay showed a broad dynamic range. Of 148 commercial samples, the 73-10 assay with ≥1%, ≥50% and ≥80% cut-offs classified 64.2%, 36.5% and 23.6% of samples as PD-L1+, respectively, whereas 20.3% were PD-L1+ with the 22C3 assay at a pre-specified ≥50% cut-off. The overall percentage agreement between assays was 83.8% using the ≥50% cut-off for both assays, and 93.9% using the ≥80% cut-off for 73-10 and ≥50% for 22C3. In follow-up studies, 83 study samples from the 1L NSCLC cohort were evaluable with both assays. With the 73-10 assay at ≥1%, ≥50%, and ≥80% cut-offs, 79.5%, 45.8%, and 31.3% of study tumors, respectively, were PD-L1+; with the 22C3 assay at ≥1% and ≥50% cut-offs, 59.0% and 21.7% were PD-L1+. Conclusions: Using a high tumor cell PD-L1 staining cut-off, the 73-10 and 22C3 assays showed highly concordant staining of NSCLC samples, with similar sensitivity observed with an ≥80% cut-off for 73-10 and ≥50% for 22C3. Using a low frequency of tumor PD-L1 expression, data suggested that the 73-10 assay had greater sensitivity than the 22C3 assay. These results provide a rationale for additional studies using the 73-10 assay at various cut-offs within the avelumab trial program. Clinical trial information: NCT01772004.
Iron deficiency anaemia in oncology: an epidemiological prospective study
Authors: J. Barriere, J.-M. Ferrero, B. Hoch, R. Largillier, C. Hebert, D. Borchiellini, P. Follana, V. Mari, L. Evesque, E. Saada-Bouzid, R. Schiappa, V. Raimondi, E. Chamorey, J. Viotti
Journal: Annals of Oncology (2017)
Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
Authors: L. Horvath, J. Desai, S. Sandhu, A. O'Donnell, A.G. Hill, S. Deva, B. Markman, M.B. Jameson, Z. Chen, X. Tan, J. Hou, A. Lim
Journal: Annals of Oncology (2017)
Prognostic factors for IDH mutant molecular astrocytomas
Authors: S. Minichillo, E. Franceschi, A. Mura, A. Mandrioli, A. Tosoni, G. Tallini, A. Pession, M.P. Foschini, C. Bortolotti, D. Danieli, A. Talacchi, L. Cirillo, S. Bartolini, A. Paccapelo, A.A. Brandes
Journal: Annals of Oncology (2017)
Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression
Authors: Benjamin J. Murdock, Tingting Zhou, Samy R. Kashlan, Roderick J. Little, Stephen A. Goutman, Eva L. Feldman
Journal: JAMA Neurology (2017)

<h3>Importance</h3> Amyotrophic lateral sclerosis (ALS) has an immune component, but previous human studies have not examined immune changes over time. <h3>Objectives</h3> To assess peripheral inflammatory markers in participants with ALS and healthy control individuals and to track immune changes in ALS and determine whether these changes correlate with disease progression. <h3>Design, Setting, and Participants</h3> In this longitudinal cohort study, leukocytes were isolated from peripheral blood samples from 35 controls and 119 participants with ALS at the ALS Clinic of the University of Michigan, Ann Arbor, from June 18, 2014, through May 26, 2016. Follow-up visits occurred every 6 to 12 months. Fifty-one participants with ALS provided samples at multiple points. Immune cell populations were measured and compared between control and ALS groups. Surface marker expression of CD11b<sup>+</sup>myeloid cells was also assessed. Changes over time were correlated with disease progression using multivariate regression. <h3>Main Outcomes and Measures</h3> The number of immune cells per milliliter of blood and the fold expression of cell surface markers. Multivariate regression models were used to correlate changes in immune metrics with changes on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). <h3>Results</h3> Thirty-five controls (17 women [48.6%] and 18 men [51.4%]; mean [SD] age, 63.5 [9.9] years) and 119 participants with ALS (50 women [42.0%] and 69 men [68.0%]; mean [SD] age, 61.4 [11.5] years) were enrolled. Compared with controls, participants with ALS had increased mean (SEM) counts ( × 10<sup>6</sup>/mL) of total leukocytes (4.57 [0.29; 95% CI, 3.94-5.11] vs 5.53 [0.16; 95% CI, 5.21-5.84]), neutrophils (2.87 [0.23; 95% CI, 2.40-3.35] vs 3.80 [0.12; 95% CI, 3.56-4.04]), CD16<sup>+</sup>monocytes (0.03 [0.003; 95% CI, 0.02-0.04] vs 0.04 [0.002; 95% CI, 0.03-0.04]), CD16<sup>−</sup>monocytes (0.25 [0.02; 95% CI, 0.21-0.30] vs 0.29 [0.01; 95% CI, 0.27-0.31]), and natural killer cells (0.13 [0.02; 95% CI, 0.10-0.17] vs 0.18 [0.01; 95% CI, 0.16-0.21]). We also observed an acute, transient increase in a population of CD11b<sup>+</sup>myeloid cells expressing HLA-DR, CD11c, and CX3CR1. Finally, early changes in immune cell numbers had a significant correlation with disease progression measured by change in ALSFRS-R score, particularly neutrophils (−4.37 [95% CI, −6.60 to −2.14] per 11.47 × 10<sup>4</sup>/mL [SD, 58.04 × 10<sup>4</sup>/mL] per year) and CD4 T cells (−30.47 [95% CI, −46.02 to −14.94] per −3.72 × 10<sup>4</sup>/mL [SD, 26.21 × 10<sup>4</sup>/mL] per year). <h3>Conclusions and Relevance</h3> Changes in the immune system occur during ALS and may contribute to the pathologic features of ALS.
I’ve Had a Vision of Improved Primary Care
Authors: Brent W. Beasley
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Accuracy of diagnosis criteria in patients with suspected diagnosis of sporadic Creutzfeldt-Jakob disease and detection of 14-3-3 protein, France, 1992 to 2009
Authors: Laurene Peckeu, Nicole Delasnerie-Lauprètre, Jean-Philippe Brandel, Dominique Salomon, Véronique Sazdovitch, Jean-Louis Laplanche, Charles Duyckaerts, Danielle Seilhean, Stéphane Haïk, Jean-Jacques Hauw
Journal: Eurosurveillance (2017)

Diagnostic criteria of Creutzfeldt-Jakob disease (CJD), a rare and fatal transmissible nervous system disease with public health implications, are determined by clinical data, electroencephalogram (EEG), detection of 14-3-3 protein in cerebrospinal fluid (CSF), brain magnetic resonance imaging and prion protein gene examination. The specificity of protein 14-3-3 has been questioned. We reviewed data from 1,572 autopsied patients collected over an 18-year period (1992-2009) and assessed whether and how 14-3-3 detection impacted the diagnosis of sporadic CJD in France, and whether this led to the misdiagnosis of treatable disorders. 14-3-3 detection was introduced into diagnostic criteria for CJD in 1998. Diagnostic accuracy decreased from 92% for the 1992-1997 period to 85% for the 1998-2009 period. This was associated with positive detections of 14-3-3 in cases with negative EEG and alternative diagnosis at autopsy. Potentially treatable diseases were found in 163 patients (10.5%). This study confirms the usefulness of the recent modification of diagnosis criteria by the addition of the results of CSF real-time quaking-induced conversion, a method based on prion seed-induced misfolding and aggregation of recombinant prion protein substrate that has proven to be a highly specific test for diagnosis of sporadic CJD.
Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial
Authors: Brenda M Sandmaier, David G Maloney, Barry E. Storer, Gitte Olesen, Michael B. Maris, Jonathan A Gutman, Soren Lykke Petersen, Amelia Langston, Thomas Chauncey, Wolfgang Bethge, Michael A Pulsipher, Brian Thomas Kornblit, Ann E Woolfrey, Marco Mielcarek, Paul J. Martin, Mary E.D. Flowers, Rainer F. Storb
Journal: Blood (2016)
GW28-e1180 Comparison of one-year outcomes in myocardial infarction patients with or without ST-segment elevation caused by unprotected left main coronary artery occlusion treated by emergency PCI: data from two centers registry
Authors: Haiwei Liu, Han YaLing, Chen ShaoLiang, Jin QuanMin, Wang XiaoZeng, Ma YingYan, Wang Geng, Wang Bing, Xu Kai, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
El sarampión en Europa en 2001-2002
Authors: M Muscat, S Glismann, H Bang
Journal: Eurosurveillance (2003)

En 2001-02, EUVAC.NET recibio un total de 17.928 casos de sarampion, con un aumento del 41% entre ambos anos, lo que da una incidencia cruda del 3,37 y 2,36 por 100.000 habitantes respectivamente. Casi todos los casos declarados fueron de edades comprendidas entre uno y nueve anos. Los casos de sarampion vinculados a brotes representaron el 18% de los casos declarados en 2001 y el 20% en 2002. Menos del 1% de los casos correspondio a casos importados en 2001 y 2002. En 21 casos declarados en 2001 y en 6 casos en 2002 se produjo encefalitis como complicacion grave. En 2001 se declaro una muerte atribuida a sarampion. La proporcion de casos declarados con estado de vacunacion conocido aumento del 56% de los casos en 2001 al 72% en 2002. En general, la proporcion de casos de sarampion declarados no vacunados subio del 50% en 2001 al 66% en 2002.
Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital
Authors: A.H. Ingles Garces, J.E. Ang, M. Ameratunga, M. Chenard-Poirier, D. Dolling, N. Diamantis, S. Seeramreddi, R. Sundar, J. de Bono, J. Lopez, U. Banerji
Journal: Annals of Oncology (2017)
Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs
Authors: E. Felip Font, A.T. Shaw, B.J. Solomon, T.M. Bauer, S.-H.I. Ou, S. Gadgeel, R.A. Soo, T. Seto, J.S. Clancy, L.P. James, A. Abbattista, B. Besse
Journal: Annals of Oncology (2017)
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM-151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
Authors: S. Napolitano, G. Martini, E. Martinelli, C.M. Della Corte, V. Belli, N. Matrone, F. Morgillo, F. Ciardiello, T. Troiani
Journal: Annals of Oncology (2017)
High thromboembolic event rate in patients with locally advanced esophageal cancer during perioperative therapy: A pre-planned analysis of the intergroup phase III trial SAKK 75/08
Authors: M. Fehr, H. Hawle, S. Hayoz, P. Thuss-Patience, S. Schacher, J. Riera Knorrenschild, D. Dürr, W.T. Knoefel, H. Rumpold, M. Bitzer, M. Zweifel, P. Samaras, U. Mey, R. Winterhalden, M. Kueng, W. Eisterer, V. Hess, M-A. Gerard, M. Stahl, T. Ruhstaller
Journal: Annals of Oncology (2017)
Abstract 11677: Associations Between Proton Pump Inhibitors and Low Cardiac Mortality in Patients With Heart Failure
Authors: Mai Takiguchi, Akiomi Yoshihisa, Yu Sato, Shunsuke Watanabe, Tetsuro Yokokawa, Shunsuke Miura, Takamasa Sato, Satoshi Suzuki, Masayoshi Oikawa, Atsushi Kobayashi, Takayoshi Yamaki, Hiroyuki Kunii, Shu-ichi Saitoh, Yasuchika Takeishi
Journal: Circulation (2016)

Background: It has been recently reported that use of histamine H 2 receptor blocker (H2RA) is associated with the blockade of right and left ventricular remodeling and reduces risk of incident heart failure (HF) in cohort of participants without cardiovascular diseases. However, the association between acid suppressive therapy such as H2RA or proton pump inhibitor (PPI) and cardiac mortality in HF patients is still unclear. Therefore, we examined impacts of the acid suppressive therapy on cardiac mortality in HF patients. Methods and Results: We analyzed consecutive 1191 HF patients. These patients were divided into 3 groups: no acid suppressive therapy group (None, n = 363), H2RA group (n = 164) and PPI group (n = 664). Although presence of male gender, diabetes, atrial fibrillation and reduced left ventricular ejection fraction did not differ among the three groups, prevalence of ischemic etiology, dyslipidemia, chronic kidney disease, anemia and past history of peptic ulcer was higher in PPI group than in H2RA and no acid suppressive therapy groups (ischemic etiology 32.2% vs. 27.4% and 15.7%, p&lt;0.001; dyslipidemia 79.2% vs. 77.4% and 70.5%, p=0.007; chronic kidney disease 62.8% vs. 57.3% and 53.2%, p=0.010; anemia 64.0% vs. 54.3% and 46.0%, p&lt;0.001; peptic ulcer 15.1% vs. 7.9% and 6.3%, p&lt;0.001). In the follow-up period (mean 995 days), 169 cardiac deaths occurred. In the Kaplan-Meier analysis, cardiac mortality was significantly lower in PPI group than in H2RA and no acid suppressive therapy groups (11.0% vs. 21.3% and 16.8%, respectively, p&lt;0.05). In the multivariable Cox proportional hazard analysis after adjusting for other potential confounding factors, use of PPI, but not H2RA, was an independent predictor of cardiac mortality in HF patients (PPI, HR 0.475, P&lt;0.001 and H2RA, HR 0.968, P=0.881). Conclusion: Proton pump inhibitors may be associated with better outcome in patients with heart failure.
P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer
Authors: C. Eng, M. Fakih, M. Amin, V. Morris, H.S. Hochster, P.M. Boland, H. Uronis
Journal: Annals of Oncology (2017)
RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer
Authors: Yifan Wang, Jayanthi Gudikote, Uma Giri, Jun Yan, Weiye Deng, Rui Ye, Wen Jiang, Nan Li, Brian P. Hobbs, Jing Wang, Stephen G. Swisher, Junya Fujimoto, Ignacio I. Wistuba, Ritsuko Komaki, John V. Heymach, Steven H. Lin
Journal: Clinical Cancer Research (2017)

Purpose: Although postoperative radiotherapy is often used to maintain local control after surgical resection and chemotherapy for locally advanced non-small cell lung cancer (NSCLC), both locoregional failure and distant metastasis remain problematic. The mechanisms of therapeutic resistance remain poorly understood.Experimental Design: We used reverse-phase protein arrays (RPPA) to profile the baseline expression of 170 total and phosphorylated proteins in 70 NSCLC cell lines to categorize pathways that may contribute to radiation resistance. Significant markers identified by RPPA were further analyzed in tissue microarrays (TMA) of specimens from 127 patients with NSCLC who had received surgery before receiving postoperative radiotherapy. Cox regression analysis and log-rank tests were used to identify potential predictive factors. We then validated the biological function of the markers in NSCLC cell lines in vitroResults: Of the 170 proteins or phospho-proteins profiled, a subset of 12 proteins was found to correlate with radiation response parameters. TMA analysis of the 12 proteins showing the greatest differences in expression in the RPPA analysis demonstrated that RAD50 had the strongest correlation with distant relapse-free survival, locoregional relapse-free survival, and disease-free survival in patients with NSCLC. We confirmed that knockdown of RAD50 sensitized NSCLC cells to radiation and that upregulation of RAD50 increased radioresistance in in vitro experiments.Conclusions: Upregulated RAD50 may be a predictor of radioresistance in patients with lung cancer who received radiotherapy. Clin Cancer Res; 24(2); 341-50. ©2017 AACR.
NGS for detection of mutations of the EGFR gene in plasma DNA of patients with the lung cancer
Authors: E. Pisareva, E. Gornostaeva, P. Gervas, N. Gutkina, A. Kudryavtsev, N. Cherdyntseva, I. Karpov, V. Shamanin, S. Kovalenko
Journal: Annals of Oncology (2017)